
June 11 (Reuters) - Vaxart Inc VXRT.O:
VAXART REPORTS POSITIVE CLINICAL DATA DEMONSTRATING THAT ITS SECOND-GENERATION VACCINE TECHNOLOGY PRODUCES MUCH STRONGER ANTIBODY RESPONSES THAN ITS FIRST-GENERATION TECHNOLOGY
VAXART INC: VACCINE CANDIDATES WERE SAFE AND WELL-TOLERATED ACROSS ALL DOSE GROUPS WITH NO VACCINE-RELATED SERIOUS ADVERSE EVENTS REPORTED
VAXART INC - VACCINE CANDIDATES SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS
VAXART INC - PHASE 3 TRIAL COULD BEGIN AS EARLY AS 2026
VAXART: SECOND-GENERATION NOROVIRUS CONSTRUCTS PRODUCE STATISTICALLY SIGNIFICANT RISES IN GI.1 & GII.4 BLOCKING ANTIBODIES VERSUS FIRST-GENERATION